influenza A (H5N1) inactivated split-virion vaccine + adjuvant

The influenza A (H5N1) inactivated split-virion vaccine + adjuvant is a monovalent vaccine designed to provide active immunization against the H5N1 subtype of the influenza A virus, commonly known as avian flu. The vaccine is produced by inactivating the virus and then using detergents to "split" the viral particles, a process that maintains the immunogenicity of key surface antigens like hemagglutinin (HA) and neuraminidase (NA) while reducing the risk of systemic adverse reactions compared to whole-virus vaccines. Because H5N1 antigens are typically poorly immunogenic in humans, the vaccine is formulated with an adjuvant—most commonly oil-in-water emulsions such as AS03 or MF59, or aluminum salts—to enhance the magnitude and breadth of the immune response. This adjuvanted approach also enables "dose-sparing," allowing for a lower amount of antigen per dose, which is a critical strategy for maximizing vaccine supply during a potential pandemic. Several versions of this vaccine have been developed and stockpiled by various governments, with GSK's AS03-adjuvanted split-virion vaccine (Q-Pan/Adjupan) being one of the most prominent examples.

Brand names

AdjupanQ-PanHumenza

Other names

prepandemic influenza vaccine (H5N1)H5N1 split-virion vaccineH-5N1 split-virion vaccineH 5N1 split-virion vaccineadjuvanted H5N1 influenza vaccine